630 related articles for article (PubMed ID: 11113727)
1. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
2. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
[TBL] [Abstract][Full Text] [Related]
3. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract][Full Text] [Related]
4. Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: modeling and external validation.
Windisch P; Becker I; Tang H; Schröder C; Buchali A; Aebersold DM; Zwahlen DR; Förster R; Shelan M
BMC Urol; 2024 Feb; 24(1):28. PubMed ID: 38310268
[TBL] [Abstract][Full Text] [Related]
5. Worse Urinary, Sexual and Bowel Function Cause Emotional Distress and Vice Versa in Men Treated for Prostate Cancer.
Orom H; Biddle C; Underwood W; Nelson CJ
J Urol; 2018 Jun; 199(6):1464-1469. PubMed ID: 29288122
[TBL] [Abstract][Full Text] [Related]
6. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
Khairnar R; Pugh SL; Sandler HM; Lee WR; Villalonga Olives E; Mullins CD; Palumbo FB; Bruner DW; Shaya FT; Bentzen SM; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Albert M; Currey AD; Pisansky TM; Chen Y; Horwitz EM; DeNittis AS; Feng FY; Mishra MV
PLoS One; 2021; 16(4):e0249123. PubMed ID: 33852571
[TBL] [Abstract][Full Text] [Related]
7. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]).
Kellogg Parsons J; Zahrieh D; Patel D; Mohler JL; Chen RC; Paskett ED; Liu H; Peil ES; Rock CL; Hahn O; Taylor J; Van Veldhuizen PJ; Small EJ; Morris MJ; Naughton MJ; Pierce JP; Marshall J
Eur Urol Focus; 2022 Nov; 8(6):1607-1616. PubMed ID: 35504836
[TBL] [Abstract][Full Text] [Related]
8. External validation of predictive models of sexual, urinary, bowel and hormonal function after surgery in prostate cancer subjects.
Borg MA; O'Callaghan ME; Moretti KL; Vincent AD
BMC Urol; 2024 Jan; 24(1):2. PubMed ID: 38166977
[TBL] [Abstract][Full Text] [Related]
9. Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer.
Tavlarides AM; Ames SC; Thiel DD; Diehl NN; Parker AS
Psychooncology; 2015 Apr; 24(4):451-7. PubMed ID: 24953309
[TBL] [Abstract][Full Text] [Related]
10. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
Löffeler S; Bertilsson H; Müller C; Aas K; Haugnes HS; Aksnessæther B; Pesonen M; Thon K; Tandstad T; Murtola T; Poulsen MH; Nordstrøm T; Vigmostad MN; Ottosson F; Holmsten K; Christiansen O; Slaaen M; Haug ES; Storås AH; Asphaug L; Rannikko A; Brasso K;
BJU Int; 2024 Jun; 133(6):680-689. PubMed ID: 38469686
[TBL] [Abstract][Full Text] [Related]
11. Missingness in the expanded prostate cancer index short form (EPIC-26) - prevalence, patterns, and explanatory factors.
Talvitie AM; Helminen M; Ojala H; Tammela T; Auvinen A; Pietilä I
Health Qual Life Outcomes; 2023 Aug; 21(1):89. PubMed ID: 37580759
[TBL] [Abstract][Full Text] [Related]
12. Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).
Lemanska A; Chen T; Dearnaley DP; Jena R; Sydes MR; Faithfull S
Qual Life Res; 2017 Aug; 26(8):2103-2116. PubMed ID: 28352980
[TBL] [Abstract][Full Text] [Related]
13. Military service and health-related quality of life among gay and bisexual prostate cancer survivors: Results from the
Bates AJ; Mitteldorf D; Rosser BRS; Wheldon CW; Polter EJ; Ross MW; Talley KMC; Haggart R; Wright MM; West W; Konety BR
BMJ Mil Health; 2024 Mar; ():. PubMed ID: 38548328
[TBL] [Abstract][Full Text] [Related]
14. Late, persistent, substantial treatment-related symptoms (LAPERS) following low-dose-rate brachytherapy for prostate cancer.
Ong WL; Millar J
Brachytherapy; 2023; 22(4):524-530. PubMed ID: 36707331
[TBL] [Abstract][Full Text] [Related]
15. Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer.
Tallman JE; Wallis CJD; Zhao Z; Huang LC; Penson DF; Koyama T; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Hoffman KE; Barocas DA
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):787-794. PubMed ID: 36482081
[TBL] [Abstract][Full Text] [Related]
16. Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment.
Lemanska A; Poole K; Manders R; Marshall J; Nazar Z; Noble K; Saxton JM; Turner L; Warner G; Griffin BA; Faithfull S
Support Care Cancer; 2022 Jan; 30(1):347-358. PubMed ID: 34286350
[TBL] [Abstract][Full Text] [Related]
17. Measuring health-related quality of life (HRQOL) in osteoporotic males using the Male OPAQ.
Solimeo SL; Silverman SL; Calderon AD; Nguyen A; Gold DT
Osteoporos Int; 2012 Mar; 23(3):841-52. PubMed ID: 21528362
[TBL] [Abstract][Full Text] [Related]
18. Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications.
Sohn W; Resnick MJ; Greenfield S; Kaplan SH; Phillips S; Koyama T; Goodman M; Hamilton AS; Hashibe M; Hoffman KE; Paddock LE; Stroup AM; Wu XC; Penson DF; Barocas DA
Med Care; 2016 Aug; 54(8):738-44. PubMed ID: 27219634
[TBL] [Abstract][Full Text] [Related]
19. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).
Yount S; Cella D; Banik D; Ashraf T; Shevrin D
Health Qual Life Outcomes; 2003 Nov; 1():69. PubMed ID: 14633279
[TBL] [Abstract][Full Text] [Related]
20. Validation of Visual Prostate Symptom Score (VPSS) in Brazilian Sample Population.
Lopes MHBM; D'Ancona CAL; Moretti TBC; Higa R; Victal ML; Camisão AR; Braga DA; Reis LO
J Wound Ostomy Continence Nurs; 2023 Jul-Aug 01; 50(4):326-330. PubMed ID: 37467413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
